You are viewing: India Cancer Biomarkers Market analysis
Part of: Cancer Biomarkers Market (Global)

The India Cancer Biomarkers Market was valued at $558.8 Million in 2026 and projected to reach to $1297.5 Million by 2031, representing a compound annual growth rate of 15.1%. India's cancer biomarkers market is positioned for exceptional growth, driven by escalating cancer burden, improved healthcare accessibility, and rising awareness of precision oncology.

India Cancer Biomarkers Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Cancer Biomarkers Market Trends and Insights

  • This accelerated growth in India significantly outpaces the global average of 11.6%, driven by rising cancer incidence, increasing healthcare investments, and growing adoption of precision medicine across Indian healthcare systems.
  • India's expanding middle class and improving diagnostic infrastructure are catalyzing demand for advanced biomarker testing solutions. The Indian cancer biomarkers market benefits from government initiatives promoting early cancer detection and personalized treatment approaches.
  • India's pharmaceutical and diagnostics sectors are increasingly integrating biomarker-driven therapies into clinical practice, supported by regulatory frameworks and collaborations between domestic and international players.
  • Between 2026 and 2031, India is expected to emerge as a key growth hub in the Asia Pacific region, with enhanced laboratory capabilities and rising awareness among healthcare providers and patients driving market penetration..

Key Market Statistics

  • CAGR (2026-2031) 15.1% CAGR
  • Market Size, 2026 ~USD 558.8 Million
  • Forecast, 2031 ~USD 1297.5 Million
  • Country India

India Cancer Biomarkers Market Overview

Rapid Market Expansion :

India's cancer biomarkers market is projected to grow from USD 558.8 million in 2026 to USD 1,297.5 million by 2031, with a CAGR of 15.1%, significantly outpacing the global growth rate of 11.6%.

Rising Cancer Incidence :

Increasing prevalence of cancer cases across India is driving demand for early detection and diagnostic biomarkers, creating substantial opportunities for market players in oncology diagnostics.

Precision Medicine Adoption :

Growing adoption of precision medicine and personalized cancer treatment approaches in India is accelerating the integration of biomarker testing into clinical practice and treatment protocols.

Healthcare Investment Surge :

Increased government and private sector investments in healthcare infrastructure and diagnostic capabilities are strengthening the foundation for cancer biomarker market growth across Indian healthcare systems.

India Cancer Biomarkers Market Dynamics

  • The country's young population, combined with lifestyle changes and increased screening initiatives, is fueling demand for advanced diagnostic solutions.
  • Healthcare providers and diagnostic laboratories are increasingly adopting biomarker-based testing to enhance treatment outcomes and reduce healthcare costs. The market expansion is further supported by government initiatives promoting early cancer detection and personalized medicine frameworks.
  • With growing collaboration between international diagnostic companies and Indian healthcare institutions, the market is expected to witness significant technological advancement and product innovation.
  • This trajectory positions India as a high-growth market within the Asia-Pacific region for cancer biomarkers..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • India's cancer biomarkers market is projected to grow from USD 558.8 million in 2026 to USD 1,297.5 million by 2031 at a 15.1% CAGR, outpacing global growth rates.
      • Rising cancer prevalence and government healthcare initiatives in India are accelerating adoption of precision medicine and biomarker-driven diagnostics.
      • India's expanding diagnostic infrastructure and growing pharmaceutical sector investments are strengthening the competitive landscape for cancer biomarker solutions.
      • The Indian market is positioned as a high-growth opportunity within Asia Pacific, driven by increasing awareness and improving access to advanced testing technologies.

      Cancer Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment LUNG CANCER (Cancer Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 11.6% from 2026 to 2031
      Largest Segment OMICS TECHNOLOGIES (Profiling Technology)
      Market Size Base Year (Billions) ~USD 28.2 (2026)
      Revenue Forecast (Billions) ~USD 48.82 (2031)
      Segments Covered Profiling Technology, Type, Cancer Type, Products

      India Cancer Biomarkers Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Profiling Technology

      • Imaging Technologies
      • Omics Technologies

      By Type

      • 2D Gel Electrophoresis
      • Antibodies
      • Biopsy Instruments
      • Computed Tomography (Ct)
      • Genomics
      • Imaging Instruments
      • Immunoassay
      • In-Situ Hybridization (Ish)
      • Kits And Reagents
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mass Spectrometry
      • Next Generation Sequencing
      • Other Omics Technologies
      • Other Proteomics Technologies
      • Pathology-Based Instrument
      • Polymerase Chain Reaction
      • Positron Emission Tomography (Pet)
      • Probes
      • Protein Microarray
      • Proteomics
      • Ultrasound Imaging

      By Cancer Type

      • Bladder Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Kidney Cancer
      • Leukemia
      • Lung Cancer
      • Melanoma
      • Non-Hodgkin'S Lymphoma
      • Other Cancer Types
      • Prostate Cancer
      • Thyroid Cancer

      By Products

      • Bioinformatics Software
      • Consumables
      • Instruments

      INDIA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032

      Segment20242025202620272029203020312032CAGR (%)
      BIOPHARMACEUTICAL COMPANIES & CROS145162.9185.6212.1280.5325.3379.6443.315.6
      DIAGNOSTIC LABORATORIES350.8389437.3493.3635726.5836.3963.514.1
      OTHER END USERS2628.130.733.740.945.450.756.710.8
      RESEARCH AND ACADEMIC INSTITUTES85.996108.8123.8162187217.1252.315
      TOTAL607.8676762.3862.81118.31284.11483.71715.814.5

      Target Audience

      • Diagnostic Companies & IVD Manufacturers : Need India-specific market data to assess market opportunity, plan product launches, identify distribution channels, and develop competitive strategies for cancer biomarker diagnostic solutions.
      • Pharmaceutical & Biotech Companies : Require detailed India market insights to support companion diagnostic development, precision medicine initiatives, and strategic partnerships with Indian healthcare institutions and diagnostic labs.
      • Healthcare Investors & Private Equity : Seek validated market sizing and growth projections for India to evaluate investment opportunities in diagnostic companies, healthcare platforms, and oncology-focused healthcare ventures.
      • Hospital Networks & Diagnostic Centers : Need market intelligence to understand biomarker testing demand, plan service expansion, invest in diagnostic infrastructure, and align offerings with precision medicine trends in India.
      • Government & Healthcare Policy Bodies : Require market data to inform healthcare policy, diagnostic infrastructure planning, cancer screening programs, and precision medicine initiatives at national and state levels in India.

      Key Companies in the India Cancer Biomarkers Market

      CompanyHQOwnershipStrongest segments
      NANOSTRING TECHNOLOGIES, INCUnited States
      CELL SIGNALING TECHNOLOGY, INC.United States
      TRANSGENOMIC, INC.United States
      SANOFISpain
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging-based biomarker systems and software,In-vitro diagnostics instruments and consumables,Varian oncology platforms and services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyInstruments (flow cytometers, analyzers, automation),Consumables & reagents (antibodies, kits, collection products, media),
      MYRIAD GENETICSUnited StatesPublic CompanyHereditary cancer and germline oncology tests (e.g., MyRisk, BRACAnalysis CDx),Tumor-based prognostic and companion diagnostics (MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Other oncology-adjacent genomics and lab services within cancer workflows,
      SYSMEX CORPORATIONJapanPublic CompanyInstruments (hematology, coagulation, cell analysis platforms),Consumables (reagents, calibrators, controls, software-linked services),
      HOLOGIC, INC.United StatesPrivate CompanyBreast cancer imaging systems and software,Biopsy guidance systems and markers,Cytology and related consumables (ThinPrep),

      NANOSTRING TECHNOLOGIES, INC

      NanoString Technologies develops and commercializes molecular analysis platforms for gene expression profiling and genomic research.

      CELL SIGNALING TECHNOLOGY, INC.

      Cell Signaling Technology Inc. produces research antibodies, proteins, and assay kits for cell biology and life sciences research.

      TRANSGENOMIC, INC.

      Transgenomic Inc. provides genetic testing and molecular diagnostics solutions for disease detection and management.

      SANOFI

      Sanofi is a multinational pharmaceutical company developing and marketing medicines, vaccines, and diagnostic products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a global medical technology company providing diagnostic imaging, laboratory diagnostics, and healthcare IT solutions.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company manufactures and distributes medical devices, laboratory equipment, and diagnostic systems.

      MYRIAD GENETICS

      Myriad Genetics is a molecular diagnostics company providing genetic testing and precision medicine solutions for cancer and other diseases.

      SYSMEX CORPORATION

      Sysmex Corporation manufactures and sells hematology, hemostasis, and clinical chemistry diagnostic systems and reagents.

      HOLOGIC, INC.

      Hologic Inc. develops and markets diagnostic and medical imaging systems, particularly for women's health and cancer detection.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Access precise market valuation for India (USD 558.8M in 2026) and verified 5-year forecast data to support investment decisions, business planning, and competitive positioning in the high-growth Indian market.
      • India-Specific Growth Drivers : Understand localized factors driving 15.1% CAGR—including rising cancer incidence, healthcare investments, and precision medicine adoption—to tailor market entry and expansion strategies for India.
      • Competitive Intelligence : Benchmark your organization against market trends specific to India's cancer biomarkers landscape, identify white-space opportunities, and develop targeted go-to-market strategies for Indian healthcare providers and diagnostic centers.
      • Regulatory & Healthcare Landscape Insights : Gain actionable intelligence on India's healthcare infrastructure, diagnostic adoption rates, and regulatory environment to navigate market entry, partnerships, and product commercialization effectively.
      • Strategic Investment Planning : Leverage India-focused market data to evaluate investment opportunities, assess market potential for biomarker products, and make informed decisions on R&D allocation and resource deployment in the region.

      Frequently asked questions

      What is the projected market size of cancer biomarkers in India by 2031?

      India's cancer biomarkers market is projected to reach USD 1,297.5 million by 2031, growing from USD 558.8 million in 2026 at a 15.1% CAGR.

      Why is India's cancer biomarkers market growing faster than the global average?

      India's 15.1% CAGR exceeds the global 11.6% due to rising cancer incidence, government healthcare investments, expanding diagnostic infrastructure, and increasing adoption of precision medicine in Indian healthcare systems.

      What are the main drivers of cancer biomarkers adoption in India?

      Key drivers include growing cancer prevalence, government initiatives for early detection, expanding middle-class population, improving laboratory capabilities, and increasing collaboration between domestic and international diagnostics companies.

      Which cancer biomarker segments are most relevant in India?

      India's market encompasses protein biomarkers, genetic biomarkers, and imaging biomarkers, with demand driven by breast cancer, lung cancer, and colorectal cancer screening and treatment monitoring.

      How does India's market position compare within Asia Pacific?

      India is emerging as a high-growth hub within Asia Pacific, with its 15.1% CAGR and expanding healthcare infrastructure positioning it as a key market for cancer biomarker solutions through 2031.

      RESEARCH METHODOLOGY

      The objective of the study is to analyze key market dynamics, including drivers, opportunities, restraints, challenges, and key players' strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the cancer biomarkers market will be analyzed, and market players will be evaluated on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
      The four steps involved in estimating the market size are

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.

      The following is a breakdown of the primary respondents

      Cancer Biomarkers Market Size, and Share

      Note 1: Others include sales, marketing, and product managers.
      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

      COMPANY NAME

      DESIGNATION

      Thermo Fisher (US)

      Sales Manager

      F. Hoffmann-La Roche AG (Switzerland)

      Product Manager

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total market size of cancer biomarkers. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research
      • The revenues generated by leading players operating in the cancer biomarkers market have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cancer Biomarkers Market : Top-Down and Bottom-Up Approach

      Cancer Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the process described above, the total market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cancer biomarkers are biological molecules produced by the body or a tumor in a person with cancer. Cancer biomarker testing helps differentiate alterations in the tumor. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. It can also be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. Biomarkers can be DNA, RNA, proteins, or metabolomic profiles specific to the tumor. They enhance cancer detection and facilitate high-speed, noninvasive diagnosis using profiling technologies such as omics, imaging, immunoassays, and cytogenetics.

      Key Stakeholders

      • Product Manufacturers, Distributors, and Suppliers
      • Diagnostic Laboratories
      • Research Laboratories and CROs
      • Ambulatory Testing Centers
      • Contract Testing Laboratories
      • Academic Universities and Medical Research Centers
      • Research and Development (R&D) Centers

      Report Objectives

      • To define, segment, and forecast the cancer biomarkers market by profiling technology, cancer type, product, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
      • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary company evaluation matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI on the market, along with the macroeconomic outlook for each region

      Available customizations:

      MarketsandMarkets offers the following customizations for this market report.

      Product Analysis

      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cancer biomarkers market

      Country Information

      • Additional country-level analysis of the cancer biomarkers market

      Company Profiles

      • Additional five company profiles of players operating in the cancer biomarkers market.

      Get the Full Cancer Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Cancer Biomarkers Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status